Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders to treat patients in moments of crisis. Using new clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate istaroxime being developed as a first-in-class treatment for acute heart failure and early cardiogenic shock in heart failure. Windtree has also focused on developing AEROSURF® as a non-invasive surfactant treatment for premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee's HK, while Windtree evaluates other uses for its synthetic KL4 surfactant for the treatment of acute pulmonary conditions including lung injury due to viral, chemical and radiation induced insults. Also, in its portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.
Company profile
Ticker
WINT
Exchange
Website
CEO
Craig E. Fraser
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
Former names
ANSAN INC, ANSAN PHARMACEUTICALS INC, DISCOVERY LABORATORIES INC /DE/
SEC CIK
Corporate docs
IRS number
943171943
WINT stock data
News
Stocks That Hit 52-Week Lows On Friday
27 May 22
Stocks That Hit 52-Week Lows On Thursday
26 May 22
Stocks That Hit 52-Week Lows On Wednesday
25 May 22
25 Stocks Moving in Tuesday's Pre-Market Session
24 May 22
Windtree Highlights Presentation Of Data From Positive SEISMiC Phase 2 Study Of Istaroxime In Early Cardiogenic Shock In Late-Breaker Presentation At The European Society Of Cardiology Heart Failure Meeting
23 May 22
Press releases
Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid
23 May 22
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
5 May 22
Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference
20 Apr 22
Investment data
Securities sold
Number of investors
Calendar
4 May 22
29 Jun 22
31 Dec 22
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 15.54M | 15.54M | 15.54M | 15.54M | 15.54M | 15.54M |
| Cash burn (monthly) | 2.27M | 1.91M | 2.78M | 6.42M | 2.24M | 2.03M |
| Cash used (since last report) | 6.73M | 5.67M | 8.24M | 19.03M | 6.64M | 6.01M |
| Cash remaining | 8.81M | 9.87M | 7.3M | -3.49M | 8.9M | 9.53M |
| Runway (months of cash) | 3.9 | 5.2 | 2.6 | -0.5 | 4.0 | 4.7 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 7 Jun 22 | Geffken Daniel E. | Common Stock | Grant | Acquire A | No | No | 0 | 5,000 | 0 | 7,069 |
| 7 Jun 22 | Geffken Daniel E. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.47 | 7,500 | 3.53K | 7,500 |
| 7 Jun 22 | Huang James | Common Stock | Grant | Acquire A | No | No | 0 | 5,000 | 0 | 296,281 |
| 7 Jun 22 | Huang James | Stock Option Common Stock | Grant | Acquire A | No | No | 0.47 | 7,500 | 3.53K | 7,500 |
| 7 Jun 22 | Robert A Scott | Common Stock | Grant | Acquire A | No | No | 0 | 5,000 | 0 | 5,000 |
| 7 Jun 22 | Robert A Scott | Stock Option Common Stock | Grant | Acquire A | No | No | 0.47 | 7,500 | 3.53K | 7,500 |
| 7 Jun 22 | Williams Leslie J. | Common Stock | Grant | Acquire A | No | No | 0 | 5,000 | 0 | 5,000 |
| 7 Jun 22 | Williams Leslie J. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.47 | 7,500 | 3.53K | 7,500 |
| 16 Mar 22 | Fraser Craig | Common Stock | Buy | Acquire P | No | No | 0.9799 | 2,000 | 1.96K | 210,058 |
Institutional ownership, Q1 2022
10.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 25 |
| Opened positions | 14 |
| Closed positions | 2 |
| Increased positions | 2 |
| Reduced positions | 2 |
| 13F shares | Current |
|---|---|
| Total value | 3.92M |
| Total shares | 3.06M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Center Laboratories | 1.54M | $2.19M |
| Vanguard | 551.27K | $629K |
| Renaissance Technologies | 234.45K | $267K |
| Kepos Capital | 165K | $188K |
| Geode Capital Management | 158.75K | $180K |
| Two Sigma Advisers | 112.3K | $128K |
| Skandinaviska Enskilda Banken AB | 110.5K | $126K |
| NTRS Northern Trust | 54.39K | $62K |
| BLK Blackrock | 48.66K | $56K |
| STT State Street | 20.27K | $23K |
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
accelerated, administered, alleviate, Angiography, area, Argentina, bid, Breakthrough, Cardiology, classification, comply, conflict, consecutive, decommissioning, dedicated, deficiency, delisted, delisting, doubt, dropping, employed, endoplasmic, equipment, fail, feasibility, geopolitical, grace, greater, headcount, highest, hypoperfusion, inflation, instability, intratracheal, laboratory, Leasehold, listed, listing, meaningful, military, multicenter, Nasdaq, objective, Oxygenation, platform, priority, reconstituted, recoverability, regain, release, residual, restore, RSU, Russia, safe, safely, salvage, satisfaction, satisfy, secondarily, shorter, Society, stabilize, stable, stage, technical, Therapy, titration, topline, Ukraine
Removed:
adjust, attributable, base, borrowing, broad, calculation, classified, commensurate, compelled, credit, decision, delivered, departure, desire, dilution, discount, disruptive, diversity, dosed, employment, endo, entitled, equal, EU, expiration, expired, forecasted, fundraising, gas, generate, guaranteed, incremental, IND, intensive, Interbank, life, mature, medicine, MPEEM, noninvasively, penetration, plasmic, pledged, portion, prepare, present, priced, pro, prorated, rata, reduction, reflect, renewed, revolving, separation, sum, TAIBOR, Taipei, target, unknown, validation, variation
Financial reports
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Jun 22
8-K
Other Events
6 Jun 22
8-K
Amendments to Articles of Incorporation or Bylaws
3 Jun 22
8-K
The study met its primary endpoint of improved systolic blood pressure (SBP) profile at 6 hours
23 May 22
8-K
Changes in Registrant's Certifying Accountant
11 May 22
8-K
Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates
5 May 22
8-K
Windtree Announces Positive Topline Results from Its
20 Apr 22
8-K
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
31 Mar 22
8-K
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
15 Mar 22
8-K
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
10 Nov 21
Registration and prospectus
S-8
Registration of securities for employees
18 May 22
S-8
Registration of securities for employees
18 May 22
424B5
Prospectus supplement for primary offering
24 Mar 21
424B5
Prospectus supplement for primary offering
22 Mar 21
S-8
Registration of securities for employees
12 Feb 21
S-8
Registration of securities for employees
12 Feb 21
S-3
Shelf registration
17 Sep 20
424B4
Prospectus supplement with pricing info
21 May 20
S-1/A
2020 Q1
IPO registration (amended)
18 May 20
Proxies
DEFA14A
Additional proxy soliciting materials
3 Jun 22
DEF 14A
Definitive proxy
30 Apr 21
DEF 14C
Information statement
29 Dec 20
DEF 14C
Information statement
18 Jul 19
PRER14C
Preliminary revised information
17 Jul 19
PRE 14C
Preliminary information
24 Jun 19
DEF 14C
Information statement
31 Dec 18
DEF 14C
Information statement
3 Dec 17
PRE 14C
Preliminary information
21 Nov 17
Other
EFFECT
Notice of effectiveness
4 Jan 22
CORRESP
Correspondence with SEC
28 Dec 21
UPLOAD
Letter from SEC
28 Dec 21
EFFECT
Notice of effectiveness
30 Sep 20
CORRESP
Correspondence with SEC
27 Sep 20
CORRESP
Correspondence with SEC
23 Sep 20
UPLOAD
Letter from SEC
22 Sep 20
EFFECT
Notice of effectiveness
20 May 20
CERT
Certification of approval for exchange listing
19 May 20
CORRESP
Correspondence with SEC
14 May 20
Ownership
4
WINDTREE THERAPEUTICS / Leslie J. Williams ownership change
9 Jun 22
4
WINDTREE THERAPEUTICS / ROBERT A SCOTT ownership change
9 Jun 22
4
WINDTREE THERAPEUTICS / James Huang ownership change
9 Jun 22
4
WINDTREE THERAPEUTICS / Daniel E. Geffken ownership change
9 Jun 22
4
WINDTREE THERAPEUTICS / Craig Fraser ownership change
17 Mar 22
4
WINDTREE THERAPEUTICS / Steven Simonson ownership change
15 Mar 22
4
WINDTREE THERAPEUTICS / Craig Fraser ownership change
15 Mar 22
4
WINDTREE THERAPEUTICS / Steven Simonson ownership change
7 Mar 22
4
WINDTREE THERAPEUTICS / John P. Hamill ownership change
7 Mar 22
4
WINDTREE THERAPEUTICS / Craig Fraser ownership change
7 Mar 22
Patents
Utility
Istaroxime-containing Intravenous Formulation for the Treatment of Acute Heart Failure (Ahf)
24 Feb 22
Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed.
Utility
Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)
14 Dec 21
Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed.
Utility
Istaroxime-containing Intravenous Formulation for the Treatment of Acute Heart Failure (Ahf)
19 Aug 21
Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed.
Reddit threads
Good morning! 🌞 #premarket #watchlist 04/20 $IO -awarded five-year contract with Brunei Shell Petroleum, $WINT -Positive Topline Results from Its Phase 2, $ALVR -FDA Grants Regenerative Medicine Therapy, $CRXT - meeting April 21-23 ... Also check afterhours runners and low float stocks in my app!
20 Apr 22
Transocean ($RIG) is VALUABLE- Q2 Stock Trading Ideas
1 Apr 22
Daily Discussion Thread - April 1st, 2022
1 Apr 22
Now that most penny stocks dropped quite a bit, which ones are worth taking a look at?
20 Feb 22
What high flying names from 2021 that have crashed or are in a bear markets are you looking to pick up while they are near 52 week lows?
8 Jan 22
Daily Plays October 12, 2021
11 Oct 21
THE LOUNGE/DAILY PLAYS August 10, 2021
9 Aug 21
Morning Update for Monday, 08/09/21
9 Aug 21
#premarket 08/09 $BTCM $WINT $SIC $FTFT $BITF
9 Aug 21
When people are long on a stock do they actually ride through the bull runs and not take profits before it comes back down?
5 Aug 21